FreeIn the Archives In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously April 04, 2025Vol.51 No.13By Jacquelyn Cobb
Conversation with The Cancer Letter Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State March 28, 2025Vol.51 No.12By Paul Goldberg
Capitol Hill Kennedy announces massive cuts, centralization at HHS—NCI and FDA hitAlso this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology March 28, 2025Vol.51 No.12By Claire Marie Porter and Jacquelyn Cobb
News Analysis DOD cancer research programs face 57% funding cut in year-long continuing resolutionPancreatic, lung, kidney cancer research programs eliminated March 28, 2025Vol.51 No.12By Jacquelyn Cobb
Guest Editorial Rathmell: We must support our junior colleagues“Empathy and listening is a key place to start” March 28, 2025Vol.51 No.12By W. Kimryn Rathmell
Guest Editorial Weill Cancer Hub East to investigate connections between metabolism and anti-tumor immunityWeill Cornell, Rockefeller, Princeton and the Ludwig Institute for Cancer Research showcase the power of collaboration March 28, 2025Vol.51 No.12By Jedd D. Wolchok, Joshua D. Rabinowitz and Sohail Tavazoie
Sponsored Building a nationally integrated cancer research and treatment network March 28, 2025Vol.51 No.12By Edward S. Kim
FreeIn the Archives Breast cancer activists in the 90s got DOD to fund cancer research—now that program has been gutted March 28, 2025Vol.51 No.12
News Analysis Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages March 21, 2025Vol.51 No.11By Claire Marie Porter and Jacquelyn Cobb
Guest Editorial Caught in the crossfire: The critical threats facing cancer centers, research, and patient care March 21, 2025Vol.51 No.11By Shannon McWeeney and Sorena Nadaf-Rahrov
